Sintilimab (anti-PD-1, IBI 308) is a fully human IgG4 monoclonal antibody that binds to PD-1 on the surface of T-cells, blocks the PD-1/PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells.
[1] Lin Zhang, et al. Front Oncol . 2020 Nov 26;10:594558.
















